Home Featured Page 222

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...

Microdosing LSD Makes Me a Better Mom

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling...

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the...

Same But Different: Antidepressant Mechanisms of Psilocybin and Ketamine

Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent...

1...221222223...296 Page 222 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...

Microdosing LSD Makes Me a Better Mom

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling...

Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the...

Same But Different: Antidepressant Mechanisms of Psilocybin and Ketamine

Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent...

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY